Company intelligence / Profile preview

iNGENū

Melbourne, Victoria, Australiaingenucro.com ↗

Ownership: Private
Development stage: Other

Overview

iNGENū specializes in providing FDA-compliant clinical trial services for early to mid-stage biotech companies globally. They leverage Australian regulatory advantages and government R&D incentives to reduce costs and accelerate timelines. Their team has collectively completed over 200 FDA Pre-INDS and more than 50 INDs. No proprietary clinical results as they are a service provider.

Therapeutic areas: OncologyPsychiatryOther
Modalities: Small moleculeBiologicMonoclonal antibodyCell therapyGene therapy
Industry: Contract Research Organization

Partnerships

Psyence Australia/Psyence BiomedResolutionRx Ltd/RespireRx Pharmaceuticals Inc.

Beyond the preview

Go deeper on iNGENū.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on iNGENū.

Explore the full profile